WO2021203772A1 - Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof - Google Patents
Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof Download PDFInfo
- Publication number
- WO2021203772A1 WO2021203772A1 PCT/CN2021/000075 CN2021000075W WO2021203772A1 WO 2021203772 A1 WO2021203772 A1 WO 2021203772A1 CN 2021000075 W CN2021000075 W CN 2021000075W WO 2021203772 A1 WO2021203772 A1 WO 2021203772A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- compositions
- phosphodiesterase
- compounds
- ectonucleotide pyrophosphatase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
The present invention relates to compounds of Formula (I), methods of using the compounds as ENPP1 inhibitors, and pharmaceutical compositions comprising such compounds.The compounds are useful in treating cancers and infectious diseases.
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180027402.9A CN115362150A (en) | 2020-04-09 | 2021-04-09 | ENPP1 inhibitor, composition and application thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2020/083934 | 2020-04-09 | ||
CN2020083944 | 2020-04-09 | ||
CNPCT/CN2020/083926 | 2020-04-09 | ||
CN2020083926 | 2020-04-09 | ||
CN2020083934 | 2020-04-09 | ||
CNPCT/CN2020/083944 | 2020-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021203772A1 true WO2021203772A1 (en) | 2021-10-14 |
Family
ID=78024077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/000075 WO2021203772A1 (en) | 2020-04-09 | 2021-04-09 | Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115362150A (en) |
WO (1) | WO2021203772A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019046778A1 (en) * | 2017-08-31 | 2019-03-07 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
WO2019051269A1 (en) * | 2017-09-08 | 2019-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Enpp1 inhibitors and their use for the treatment of cancer |
WO2019177971A1 (en) * | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
WO2019191504A1 (en) * | 2018-03-30 | 2019-10-03 | Mavupharma, Inc. | Ectonucleotide pyrophosphate-phosphodiesterase (enpp) conjugates and uses thereof |
WO2020140001A1 (en) * | 2018-12-28 | 2020-07-02 | Riboscience Llc | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
WO2020190912A1 (en) * | 2019-03-19 | 2020-09-24 | Stingray Therapeutics, Inc. | Quinoline and quinazoline compounds and methods of use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190282703A1 (en) * | 2018-03-13 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase (enpp) conjugates and uses thereof |
-
2021
- 2021-04-09 WO PCT/CN2021/000075 patent/WO2021203772A1/en active Application Filing
- 2021-04-09 CN CN202180027402.9A patent/CN115362150A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019046778A1 (en) * | 2017-08-31 | 2019-03-07 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
WO2019051269A1 (en) * | 2017-09-08 | 2019-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Enpp1 inhibitors and their use for the treatment of cancer |
WO2019177971A1 (en) * | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
WO2019191504A1 (en) * | 2018-03-30 | 2019-10-03 | Mavupharma, Inc. | Ectonucleotide pyrophosphate-phosphodiesterase (enpp) conjugates and uses thereof |
WO2020140001A1 (en) * | 2018-12-28 | 2020-07-02 | Riboscience Llc | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
WO2020190912A1 (en) * | 2019-03-19 | 2020-09-24 | Stingray Therapeutics, Inc. | Quinoline and quinazoline compounds and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN115362150A (en) | 2022-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002183A (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof. | |
CA2871471C (en) | Dna-pk inhibitors | |
MX2010005292A (en) | Inhibitors of human immunodeficiency virus replication. | |
EA201792529A1 (en) | Thyrosine Kinase Inhibitors | |
MXPA05009554A (en) | Cytokine inhibitors. | |
NZ708392A (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
EA201001821A1 (en) | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | |
EP4248973A3 (en) | Pyridazinone compounds and uses thereof | |
PT1902037E (en) | 2,4-diamino-pyrimidines used as aurora inhibitors | |
SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
MX2009009590A (en) | Aminopyrimidines useful as inhibitors of protein kinases. | |
EP4248972A3 (en) | Pyridazinone compounds and uses thereof | |
EA200601141A1 (en) | SULPHONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | |
EA200870282A1 (en) | AMINE DERIVATIVES | |
EA200601462A1 (en) | CONNECTIONS FOR THE TREATMENT OF DISEASES | |
EA201291038A1 (en) | PYRAZOL COMPOUNDS AS JAK INHIBITORS | |
WO2019152419A8 (en) | Prc2 inhibitors | |
EP2257161A4 (en) | Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia | |
CA3015494C (en) | Novel compositions and therapeutic methods | |
MA54653B1 (en) | Modulators of the cxcr7 piperidine receptor | |
WO2017134685A3 (en) | Novel hydrazino compounds as btk inhibitors | |
EA200501399A1 (en) | DERIVATIVES OF BENZOPIRANE THAT CAN BE USED IN THE TREATMENT OF INFLAMMATORY DISEASES | |
PH12020551994A1 (en) | Tlr7 agonists | |
CR20210460A (en) | Compounds useful in hiv therapy | |
MA41494A (en) | BENZOXABOROLE COMPOUNDS SUBSTITUTED IN POSITION 4 AND ASSOCIATED USES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21784058 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21784058 Country of ref document: EP Kind code of ref document: A1 |